

CORRECTION

Correction: The Rationale for Using Rifabutin in the Treatment of MDR and XDR Tuberculosis Outbreaks

Frederick A. Sirgel, Robin M. Warren, Erik C. Böttger, Marisa Klopper, Thomas C. Victor, Paul D. van Helden

There is an error in [Table 1](#). An AspTyr mutation is wrongly abbreviated as D516T (1). It should be listed as D516Y (1). Please see the corrected [Table 1](#) here.



OPEN ACCESS

Citation: Sirgel FA, Warren RM, Böttger EC, Klopper M, Victor TC, van Helden PD (2015) Correction: The Rationale for Using Rifabutin in the Treatment of MDR and XDR Tuberculosis Outbreaks. PLoS ONE 10(7): e0134190. doi:10.1371/journal.pone.0134190

Published: July 21, 2015

Copyright: © 2015 Sirgel et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Table 1. MICs and relative resistance of rifampicin and rifabutin in *M. tuberculosis*.

Genotype	<i>rpoB</i> Mutants (n)	Rifampicin		Rifabutin	
		MIC µg/ml	^b RR	MIC µg/ml	RR
Atypical Beijing	D516Y (1)	5.0	10	0.125	2
	D516S (4)	5.0–15	10–30	0.125–0.25	2–4
	D516V (29)	10–15	20–30	0.125–0.25	2–4
Undetermined	^a Wild-type (26)	≤0.5	-	≤0.06	-
Typical Beijing	S531L (1)	>10	>20	>1.0	>16
Atypical Beijing	Q510P (1)	>10	>20	>1.0	>16

^aTwenty-five clinical isolates with unknown genotype plus one H37Rv strain were included as controls.

^bRR indicates relative resistance: Mutant MIC/Wild-type MIC.

doi:10.1371/journal.pone.0134190.t001

Reference

1. Sirgel FA, Warren RM, Böttger EC, Klopper M, Victor TC, van Helden PD (2013) The Rationale for Using Rifabutin in the Treatment of MDR and XDR Tuberculosis Outbreaks. PLoS ONE 8(3): e59414. doi:10.1371/journal.pone.0059414 PMID: 23527189